Ultragenyx Pharmaceutical Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $673.0 | $560.0 | $434.0 | $363.3 | $351.4 |
| Operating income | -$535.0 | -$536.0 | -$569.0 | -$648.9 | -$381.7 |
| Net income | -$575.0 | -$569.0 | -$607.0 | -$707.4 | -$454.0 |
| Cash Flow Statement | |||||
| Free cash flow | -$472.0 | -$421.0 | -$519.0 | -$496.6 | -$411.8 |
Shares outstanding 98.6M · Free float 93.1%
Annual filing data through FY ended December 31, 2025; float as of September 14, 2026.